The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...
Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions ...
Addiction risks from opioid drugs come from their targeting of receptors found primarily in the central nervous system. Other pathways are associated with pain, but many research efforts to hit them ...
A novel, investigational NaV1.8 sodium channel blocker known as VX-548 reduced acute pain after abdominoplasty or bunionectomy at the highest dose, but not at lower doses, two phase II trials showed.
Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback